Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer.

Abstract : The present study was conducted in patients with metastatic breast cancer. Its aim was to identify the factors which influence progression -free survival (PFS) and overall survival (OS) after the first line of chemotherapy in patients with positive tumour hormone receptor status. The patients with early disease progression during first-line chemotherapy were not included. In total, 560 patients who achieved a stable disease or a response to first-line chemotherapy were studied. The factors identified to improve the duration of PFS or OS in multivariate analysis were: number of metastatic sites (p = .01; p = .01), metastatic sites (p = .02; p = .04), Disease free interval (p = .001; p < .0001), previous hormonal therapy (p = .03; p = ns), response to first line chemotherapy (p < .0001; p = 0.0001) and an administration of maintenance hormonal therapy (p < .0001; p = .001). The major impact obtained by maintenance hormonal treatment after first-line chemotherapy in this study seems to indicate that this strategy should be recommended in patients with an ER or PgR positive tumour.
Type de document :
Article dans une revue
Int J Med Sci, 2008, 5 (2), pp.100-5
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00484215
Contributeur : Philippe Saas <>
Soumis le : mardi 18 mai 2010 - 10:33:07
Dernière modification le : lundi 9 juillet 2018 - 13:12:02

Identifiants

  • HAL Id : inserm-00484215, version 1
  • PUBMED : 18461187

Collections

Citation

Armelle Dufresne, Xavier Pivot, Christophe Tournigand, Thomas Facchini, Thierry Alweeg, et al.. Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer.. Int J Med Sci, 2008, 5 (2), pp.100-5. 〈inserm-00484215〉

Partager

Métriques

Consultations de la notice

355